Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics has appointed Donna Polizio as its global head of market access, enhancing its leadership team. Polizio, previously a vice president at Genomic Health, will focus on promoting optical genome mapping (OGM) adoption and securing reimbursement for OGM-based tests, particularly in the U.S. She brings extensive experience in diagnostics and reimbursement strategies. Bionano's CEO, Erik Holmlin, expressed confidence that Polizio's expertise will aid in advancing the company's goals, particularly in achieving better reimbursement pathways for OGM diagnostics.
Bionano Genomics (BNGO) reported impressive Q3 2022 results, achieving 55% year-over-year revenue growth to $7.2 million, the highest in company history. The installed base of Saphyr systems grew to 217, marking an 11% increase from Q2 2022. The company increased cash reserves to $180.2 million and remains on track to meet its ELEVATE! milestones. Gross margin improved to 25% due to enhanced production yields. The fourth-quarter revenue guidance is set between $7.5 million and $8 million. A dedicated session on genome mapping at ASHG reflects OGM's rising prominence.
Bionano Genomics (Nasdaq: BNGO) released a validation study showcasing the effectiveness of optical genome mapping (OGM) compared to traditional cytogenetic methods in analyzing hematological neoplasms. The study involved 69 samples and revealed a 100% first-pass rate for OGM, with a sensitivity of 98.7%, specificity of 100%, and accuracy of 99.2%. OGM also identified additional structural variants, aiding better tumor classification and therapy selection. CEO Erik Holmlin expressed optimism about OGM’s potential as a primary cytogenomic test for hematologic malignancies.
Bionano Genomics (Nasdaq: BNGO) will participate in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022, showcasing optical genome mapping's (OGM) applications, including genetic disease and hematological malignancies. Key presentations include workshops on enhancing detection of pathogenic structural variants, and methodologies for homologous recombination deficiency assessment. The event will highlight OGM's integration with next-generation sequencing. The conference runs from November 1-5, 2022, in Phoenix, Arizona, underscoring OGM's growing recognition in molecular pathology.
Bionano Genomics (BNGO) will host a conference call and live webcast on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and corporate advancements. Investors can participate via a toll-free number or through a dedicated webcast link. The call will be accessible for replay on Bionano's investor relations website for 30 days following the event. Bionano Genomics focuses on genome analysis solutions, aiming to enhance diagnostics through its various platforms, including Lineagen and BioDiscovery.
Bionano Genomics, Inc. (BNGO) and Hamilton announced the commercial availability of the Long String VANTAGE, an automated system for high throughput isolation of ultra-high molecular weight (UHMW) DNA. This system improves the efficiency of optical genome mapping (OGM) using human blood samples, allowing labs to process up to 24 samples in an eight-hour workday. Shipping is expected to begin in Q1 2023 as part of ongoing collaboration for clinical applications. The development aims to enhance genomic analysis accuracy, reducing hands-on time and improving result consistency.
Bionano Genomics hosted its first "Meet the User" event on October 24, 2022, at its new CLIA-certified laboratories in San Diego. The event gathered over 50 participants from multiple countries, focusing on optical genome mapping (OGM). Attendees experienced hands-on demonstrations of the Saphyr system and NxClinical software, along with educational sessions on data analysis for rare diseases. Bionano aims to enhance OGM adoption and provided insights into their product roadmap, showcasing the growing interest in genomic solutions.
Bionano Genomics (BNGO) announced its participation in the ASHG Annual Meeting 2022, showcasing its optical genome mapping (OGM) technology. Key presentations include a multi-site clinical study of OGM's application in postnatal genetic disorders and significant advancements in molecular cytogenetics. The conference will feature a record 24 scientific presentations on OGM's utility in genetic disease research. Notably, Bionano will present new data from its partnership with Hamilton on the Long String VANTAGE system, enhancing ultra-high molecular weight DNA extraction processes.
Bionano Genomics (BNGO) announced a peer-reviewed study validating optical genome mapping (OGM) for noninvasive prenatal testing (NIPT) results. The research, conducted at Hangzhou Maternity and Child Care Hospital, found OGM effectively identifies complex chromosomal rearrangements (CCR) tied to recurrent pregnancy loss, with 70% of CCR carriers being phenotypically normal. The study demonstrated OGM's capability to reveal significant structural aberrations overlooked by traditional methods, improving prenatal diagnosis and genetic counseling, highlighting its potential for high-risk pregnancies.
Bionano Genomics (BNGO) announced its participation in the Spanish Society of Hematology (SEHH) 2022 Conference, taking place from October 6-8 in Barcelona. The company featured six scientific presentations showcasing the applications of its optical genome mapping (OGM) technology in hematologic malignancies like leukemias and lymphomas. These independent studies emphasize OGM's utility in cancer genomics and cytogenetic diagnosis, potentially positioning it as a vital tool for future cancer research.